The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Alternative drug formulations of docetaxel: a review
Abstract
The anticancer drug docetaxel (Taxotere) is formulated in the nonionic surfactant polysorbate 80 (Tween 80). Early in the clinical development of docetaxel, it became clear that docetaxel administration is associated with the occurrence of unpredictable (acute) hypersensitivity reactions and cumulative fluid retention. These side-effects have been attributed, in part, to the presence of polysorbate 80 and have consequently initiated research focused on the development of a less-toxic, better-tolerated polysorbate 80-free formulation of docetaxel. More recently, there is an increasing interest in developing a (polysorbate 80-free) docetaxel formulation that selectively targets malignant tissue, thereby increasing efficacy while decreasing the occurrence of side-effects related to wide and nonspecific body distribution. This review aims to discuss the preclinical and clinical results of pharmaceutical strategies [PEGylated (immuno)liposomal docetaxel, docetaxel-fibrinogen-coated olive oil droplets, docetaxel encapsulated nanoparticle-aptamer bioconjugates, submicronic dispersion formulation] to develop an alternative, solvent-free, delivery form for docetaxel characterized by increased efficacy and decreased toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Cited by
Functional Aptamers and Aptazymes in Biotechnology, Diagnostics, and Therapy
Famulok, M., Hartig, J. S., & Mayer, G. (2007) · Chemical Reviews · doi:10.1021/cr0306743 · Cited by 887
Merisko-Liversidge, E., & Liversidge, G. G. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.12.007 · Cited by 608
Controlled Drug Delivery: Historical perspective for the next generation
Yun, Y. H., Lee, B. K., & Park, K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.005 · Cited by 378
Liu, Y., Li, K., Pan, J., Liu, B., & Feng, S.-S. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.036 · Cited by 342
Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes
Gaucher, G., Marchessault, R. H., & Leroux, J.-C. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.11.012 · Cited by 315
Metadata
- Authors
- Engels, F. K., Mathot, R. A. A., & Verweij, J.
- Venue
- Anti-Cancer Drugs
- Published
- 2007-02
- Volume
- 18
- Issue
- 2
- Pages
- 95-103
- ISSN
- 0959-4973 (ISSN-L)
- OpenAlex
- W1987942958
- Cited by
- 211
- References
- 2
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alternative drug formulations of docetaxel: a review. https://app.cochat.ai/papers/10.1097/cad.0b013e3280113338
- The paper
- Engels, F. K., Mathot, R. A. A., & Verweij, J. (2007). Alternative drug formulations of docetaxel: a review. Anti-Cancer Drugs. https://doi.org/10.1097/cad.0b013e3280113338
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.